← Back to patent-cliff list
Vilzemetkib
Tier C — Watch / tradeVilzemetkib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：c-Met
Indications (approved)：Thyroid cancer, Non-small cell lung cancer, Lung cancer, Ovarian cancer, Solid tumour, Pancreatic cancer, Liver cancer, Medullary thyroid cancer
Regional status
US
-
EU
-
China
Phase III
2023-06-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vilzemetkib?
Approved indications include: Thyroid cancer, Non-small cell lung cancer, Lung cancer, Ovarian cancer, Solid tumour, Pancreatic cancer, Liver cancer, Medullary thyroid cancer.
When does the Vilzemetkib patent expire?
No public expiry year is available for Vilzemetkib yet; this page updates once verified.
How do I get a quote for Vilzemetkib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22